Sex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia: Experiences from the outcome reduction with an Initial Glargine Intervention trial.

Abstract

INTRODUCTION:

Sex hormone-binding globulin (SHBG), which binds most of circulating testosterone in blood, has been linked to dysglycemia and cardiovascular disease but the relationship with heart failure remains unclear.

AIM:

To study the relation between SHBG and heart failure hospitalizations.

METHODS:

SHBG levels were analysed in dysglycemic participants at high cardiovascular risk (n = 8401) followed for a median of 6.2 years in the Outcome Reduction with an Initial Glargine Intervention trial. Cox regression was used to estimate hazard ratios (HRs) per one standard deviation increase for heart failure hospitalizations adjusted for age, comorbidities, biochemical data (including testosterone) and pharmacological treatment.

RESULTS:

5553 men and 2848 women were included. Heart failure hospitalizations occurred in 349 (6.3 %) men and 123 (4.3 %) women. One standard deviation increase in SHBG was independently associated with an increased risk of heart failure hospitalizations in men (HR 1.15, 95 % CI 1.03-1.28; p = 0.011) but not in women (HR 1.15; 95 % CI 0.96-1.39; p = 0.14).

CONCLUSIONS:

In patients with dysglycemia and high cardiovascular risk, increasing SHBG was associated with greater risk of HF hospitalizations independent of testosterone concentrations in men but not in women, suggesting the effects could be mediated through androgen-independent pathways.

• Authors: Anne Wang, Sibylle Hess, Shun Fu Lee, Hertzel C Gerstein
• Journal: Diabetes research and clinical practice (Diabetes Res Clin Pract) Vol. 206 Pg. 111010 (Dec 2023) ISSN: 1872-8227 [Electronic] Ireland
• PMID: 37956942 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Chemical References

• Insulin Glargine
• Sex Hormone-Binding Globulin
• Testosterone

Topics

• Male
• Humans
• Female
• Insulin Glargine (therapeutic use)
• Sex Hormone-Binding Globulin (metabolism)
• Heart Failure (drug therapy)
• Testosterone
• Cardiovascular Diseases